Bray Capital Advisors Vertex Pharmaceuticals Inc Transaction History
Bray Capital Advisors
- $387 Million
- Q2 2024
A detailed history of Bray Capital Advisors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bray Capital Advisors holds 3,930 shares of VRTX stock, worth $1.79 Million. This represents 0.48% of its overall portfolio holdings.
Number of Shares
3,930
Previous 3,930
-0.0%
Holding current value
$1.79 Million
Previous $1.64 Million
12.18%
% of portfolio
0.48%
Previous 0.43%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,706Shares Held
225MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.2 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.34 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$3.89 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $117B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...